Slowing the progression of age-related hearing loss: Rationale and study design of the ASPIRIN in HEARING, retinal vessels imaging and neurocognition in older generations (ASPREE-HEARING) trial
MetadataShow full item record
© 2015. Background: Age-related hearing loss (ARHL) is a leading cause of disability in the elderly. Low-grade inflammation and microvessel pathology may be responsible for initiating or exacerbating some of the hearing loss associated with aging. A growing body of evidence demonstrates an association of hearing loss with cognitive decline. A shared etiological pathway may include a role of inflammation, alongside vascular determinants. The ASPREE-HEARING study aims to determine whether low-dose aspirin decreases the progression of ARHL, and if so, whether this decrease in progression is also associated with retinal microvascular changes and/or greater preservation of cognitive function. Design and methods: A three year double-blind, randomized controlled trial of oral 100. mg enteric-coated aspirin or matching placebo, enrolling 1262 Australians aged =. 70. years with normal cognitive function and no overt cardiovascular disease. The primary outcome is the change in mean pure tone average hearing threshold (decibels) in the better ear, over a 3-year period. Secondary outcomes consist of changes in retinal microvascular indicators, and changes in cognitive function. Participants are recruited from a larger trial, ASPirin in Reducing Events in the Elderly (ASPREE), which is designed to assess whether daily low dose aspirin will extend disability-free life. Discussion: ASPREE-HEARING will determine whether aspirin slows development or progression of ARHL, and will interrogate the relationship between inflammatory and microvascular mechanisms that may underlie the effects of aspirin on ARHL. This study will improve understanding of the patterns of comorbidity with, and the relationships between, aging and ARHL, alongside modeling the impacts of ARHL.
Showing items related by title, author, creator and subject.
Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD studyRobman, L.; Guymer, R.; Woods, R.; Ward, S.; Wolfe, R.; Phung, J.; Hodgson, L.; Makeyeva, G.; Aung, K.; Gilbert, T.; Lockery, J.; Le-Pham, Y.; Orchard, S.; Storey, E.; Abhayaratna, W.; Reid, D.; Ernst, M.; Nelson, M.; Reid, Christopher; McNeil, J. (2017)© 2017 The AuthorsPurpose Although aspirin therapy is used widely in older adults for prevention of cardiovascular disease, its impact on the incidence, progression and severity of age-related macular degeneration (AMD) ...
Aspirin for the prevention of cognitive decline in the elderly: Rationale and design of a neuro-vascular imaging study (ENVIS-ion)Reid, Christopher; Storey, E.; Wong, T.; Woods, R.; Tonkin, A.; Wang, J.; Kam, A.; Janke, A.; Essex, R.; Abhayaratna, W.; Budge, M. (2012)Background: This paper describes the rationale and design of the ENVIS-ion Study, which aims to determine whether low-dose aspirin reduces the development of white matter hyper-intense (WMH) lesions and silent brain ...
Brain and mood changes over 2 years in healthy controls and adults with heart failure and ischaemic heart diseaseAlmeida, O.; Garrido, G.; Etherton-Beer, C.; Lautenschlager, N.; Arnolda, L.; Alfonso, Helman; Flicker, L. (2013)Aims: Heart failure (HF) has been associated with cognitive dysfunction, a high prevalence of mood disorders, and a relative loss of grey matter in several brain regions. This study aimed to determine if, compared with ...